Relationship between CNS depressant and enzyme inhibitory properties of substituted quinazolone 1,3,4-oxadiazoles.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002490:Central Nervous System / Q000187:drug effects*; D055598:Chemical Phenomena; D002621:Chemistry; D002800:Cholinesterase Inhibitors; D003864:Depression, Chemical; D004952:Esters / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010069:Oxadiazoles / Q000494:pharmacology* / Q000633:toxicity; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D013882:Thiosemicarbazones / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D000700:Analgesics; D000927:Anticonvulsants; D002800:Cholinesterase Inhibitors; D004952:Esters; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D010069:Oxadiazoles; D011799:Quinazolines; D013882:Thiosemicarbazones; D062367:ortho-Aminobenzoates; D012110:Reserpine